Trimel (TSX:TRL) has acquired Canadian rights to Estrace (oral 17-beta estradiol) for C$44.5m from Shire. This profitable asset, with US$9-10m in annual sales, complements Trimel's existing hormone replacement pipeline. The transaction fits with the goal to become EBITDA positive within 12-18 months, although future Natesto-related revenue (upon completion of a partnership transaction) will be the key driver towards this objective.

Trimel is a Canadian specialty pharmaceutical company. Natesto and Tefina deliver testosterone through a bio-adhesive nasal gel drug delivery technology platform, for male hypogonadism and female orgasmic disorder (FOD), respectively. Estrace is being marketed for HRT in Canada.

To view the full report, click on the following link: http://www.edisoninvestmentresearch.com/research/report/trimel-pharmaceuticals-

To view all of Edison's recently pubished research, click here.
 

Grafico Azioni Trilogy International Pa... (TSX:TRL)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Trilogy International Pa...
Grafico Azioni Trilogy International Pa... (TSX:TRL)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Trilogy International Pa...